AllSci News
Thyora Therapeutics launches with Moffitt covalent chemistry platform
Thyora Therapeutics, a Tampa, Florida-based biotechnology company, emerged from stealth with an exclusive worldwide license to covalent chemistry technology...
Genmab and AbbVie's epcoritamab fails survival endpoint in confirmatory DLBCL trial
Genmab and AbbVie clarified on July 23 that overall survival was the sole primary endpoint in the United States for the Phase III EPCORE DLBCL-1 trial...
Proveca seeks re-examination of EMA rejection for pediatric intranasal pain spray KemSu
Denmark-based Cessatech said its commercialization partner Proveca intends to request a re-examination of a negative opinion issued by the European...
Ipsen's Bylvay fails to improve native liver survival in biliary atresia Phase III trial
Ipsen's Phase III BOLD trial of Bylvay (odevixibat) in biliary atresia did not meet its primary endpoint of improving native liver survival versus placebo,...
Infinitopes debuts off-the-shelf esophageal cancer vaccine in clinic
Oxford, England-based Infinitopes has dosed the first patient in a trial testing whether a therapeutic cancer vaccine given before surgery can lower...
J&J's Tecvayli + Talvey combo cuts progression risk 89% in earlier-line relapsed myeloma
Johnson & Johnson (NYSE: JNJ) reported that its combination of two bispecific T-cell engagers reduced the risk of disease progression or death by 89% in...
Synaptiq Therapeutics launches with acquisition of small-molecule rare disease therapy
Synaptiq Therapeutics, an Iceland-based clinical-stage biotechnology company, launched through the acquisition of SYN-001, a small molecule already in...
Transcripta secures USD 24m to advance AI-powered neurological drug platform
Palo Alto, California-based Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, has raised USD 24...
Lilly completes retatrutide Phase III package ahead of planned Q1 2027 FDA filing
Eli Lilly and Company (NYSE: LLY) reported positive topline results from two additional Phase III trials of retatrutide, pushing the investigational triple...
FDA begins review of Revolution's RAS(ON) inhibitor for pancreatic cancer
The US Food and Drug Administration has accepted for review Revolution Medicines' New Drug Application for daraxonrasib (RMC-6236), an oral RAS(ON)...
BridgeBio's encaleret advances toward first-ever ADH1 approval with FDA NDA acceptance
BridgeBio Pharma, Inc. (Nasdaq: BBIO) said the US FDA has accepted for filing its New Drug Application for encaleret, an investigational oral calcilytic, in...
N-Zyme Bio secures USD 4.6m Series A to advance pepsin-targeted reflux therapies
Delaware-based N-Zyme Biomedical, a clinical-stage biotechnology company developing pepsin-targeted therapies for reflux disease, has closed a Series A...
Royalty Pharma bets USD 425m on AstraZeneca's amyloid-clearing antibody cliramitug
New York-based Royalty Pharma plc (Nasdaq: RPRX) has agreed to buy a slice of Neurimmune's royalty interest in cliramitug, AstraZeneca's Phase III antibody...
Monopar advances first novel Wilson disease therapy in decades toward FDA approval
Monopar Therapeutics Inc. (Nasdaq: MNPR), the Wilmette, Illinois-based biopharmaceutical company, has initiated a rolling submission of a New Drug...
SKNV licenses Washington University immunotherapy patent for actinic keratosis
SKNV, a Fort Lauderdale, Florida-based compounding pharmacy and dermatology-focused drugmaker, has secured exclusive commercialization rights under a...
The AllSci Brief
Free, systematic R&D and deal news. Daily.